IMVT Immunovant, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1764013 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-9.5%
TTM EPS YoY9.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-86.5%
ROA-75.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets13.7%
Debt / equity0.00x
Current ratio7.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-17.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $85.01M | $142.63M | $142.29M | $98.92M | $114.25M | $101.20M | $93.65M | $94.52M |
| SG&A expense | $19.14M | $17.69M | $17.27M | $15.44M | $17.51M | $26.02M | $20.17M | $19.78M |
| Pretax income | -$97.25M | -$153.22M | -$150.70M | -$109.08M | -$125.91M | -$119.70M | -$105.87M | -$110.97M |
| Income tax | $0 | $0 | -$2.84M | $1.55M | $594,000 | $913,000 | $583,000 | $152,000 |
| Net income | -$97.25M | -$153.22M | -$147.86M | -$110.64M | -$126.50M | -$120.61M | -$106.45M | -$111.12M |
| EPS (basic) | -0.47 | -0.75 | — | -0.61 | -0.73 | -0.71 | — | -0.76 |
| EPS (diluted) | -0.47 | -0.75 | — | -0.61 | -0.73 | -0.71 | — | -0.76 |
| Weighted avg. shares (diluted) | 206.67M | 205.55M | — | 181.51M | 173.64M | 170.87M | — | 146.92M |
| Balance sheet | ||||||||
| Cash & equivalents | $722.27M | $797.80M | $902.11M | $994.52M | $521.87M | $598.91M | $713.97M | $374.69M |
| Receivables | $138,000 | $697,000 | $1.13M | $1.64M | $1.97M | $1.94M | $2.08M | $2.22M |
| Current assets | $760.05M | $851.18M | $948.82M | $1.04B | $573.55M | $651.76M | $767.66M | $412.54M |
| PP&E, net | $262,000 | $351,000 | $443,000 | $531,000 | $632,000 | $737,000 | $844,000 | $752,000 |
| Total assets | $760.97M | $852.49M | $957.01M | $1.05B | $582.96M | $661.44M | $776.22M | $420.93M |
| Current liabilities | $104.02M | $117.10M | $104.42M | $66.26M | $63.25M | $52.90M | $68.78M | $68.31M |
| Total liabilities | $104.02M | $117.10M | $104.42M | $66.26M | $63.25M | $52.90M | $68.78M | $68.31M |
| Shareholders' equity | $656.95M | $735.39M | $852.59M | $986.13M | $519.71M | $608.54M | $707.45M | $352.62M |
| Shares outstanding | 206.79M | 206.26M | 203.94M | 203.32M | 174.53M | 171.07M | 170.11M | 147.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$83.22M | -$124.41M | -$95.06M | -$92.33M | -$102.52M | -$117.41M | -$110.64M | -$100.39M |
| Capital expenditure | — | — | $8,000 | $0 | $0 | $0 | $201,000 | $180,000 |
| Free cash flow | — | — | -$95.07M | -$92.33M | -$102.52M | -$117.41M | -$110.84M | -$100.57M |
| Investing cash flow | — | — | -$8,000 | $0 | $0 | $0 | -$201,000 | -$180,000 |
| Financing cash flow | $7.88M | $20.10M | $3.64M | $564.60M | $24.59M | $2.92M | $450.61M | $2.46M |
| Depreciation & amortization | $89,000 | $92,000 | $96,000 | $101,000 | $105,000 | $107,000 | $109,000 | $99,000 |
| Stock-based compensation | $12.89M | $13.77M | $11.14M | $12.53M | $13.19M | $18.51M | $11.69M | $11.65M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.